Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB has no revenue and is operating at a loss, with a net income of -65.17 million SEK and an operating income of -68.99 million SEK. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure. However, the company has negative operating and free cash flows of -72.34 million SEK and -64.35 million SEK, respectively, which suggests liquidity constraints. The company's return on equity is -61.87%, and its return on assets is -40.29%, both significantly below the industry median for pharmaceutical companies. These metrics indicate poor profitability and asset utilization, which is a concern for investors. Infant Bacterial Therapeutics AB does not report revenue by segment or geography, as it is in the early stages of development and has not yet commercialized its products. The company's focus is on the clinical development of IBP-9414, which is targeted at a specific medical need in premature infants. The company's outlook for the current fiscal year is negative, with no revenue and continued losses. The next fiscal year is expected to follow a similar trajectory, with no indication of a significant change in the company's financial performance. The company's operating cash flow is expected to remain negative, and there is no indication of a near-term improvement in profitability. The company's risk assessment indicates low liquidity and low dilution risk. There are no immediate filing-based liquidity or dilution flags, suggesting that the company is not currently under financial distress. However, the company's negative cash flows and lack of revenue could pose a long-term risk to its financial stability. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's ESG controversies score is 100.0, indicating a high level of controversy, while its governance and social pillar scores are 38.5 and 9.5, respectively, which are below the industry median.